In people at high risk for type 1 diabetes, 14 days of therapy with the experimental drug teplizumab delayed development of the disease by a year or more.
Shares of Zealand Pharma A/S were up more than 2 percent after the company announced that dasiglucagon, a potential treatment for severe hypoglycemia, hit the mark in a Phase III study.
British drugmaker AstraZeneca Plc said on Monday the European Commission approved the company’s diabetes drug Forxiga for use as an oral supplement to insulin in adults with a rare type of the disease.
The U.S. Food and Drug Administration declined to approve a drug developed by Sanofi SA and Lexicon Pharmaceuticals Inc. intended for use with insulin in patients with type 1 diabetes, the companies said.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the Marketing Authorization of Zynquista (sotagliflozin), developed by Sanofi and Lexicon.
For a while now there has been a heated debate surrounding hybrid and closed loop insulin systems.
The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
